I a stylized model of biopharmaceutical contract manufacturing, this paper shows how the potential for renegotiation influences the optimal structure of supply contracts, investments in innovation and capacity, the way scarce capacity is allocated, and firms’ resulting profits. Two buyers contract for capacity with a common manufacturer. Then, the buyers invest in innovation (product developmen...